ViewRay Inc. (NASDAQ:VRAY) Director Aditya Puri acquired 1,472,803 shares of the company’s stock in a transaction that occurred on Friday, September 9th. The stock was purchased at an average cost of $2.95 per share, for a total transaction of $4,344,768.85. Following the purchase, the director now owns 18,964 shares of the company’s stock, valued at $55,943.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Shares of ViewRay Inc. (NASDAQ:VRAY) opened at 4.56 on Tuesday. The stock’s market cap is $175.09 million. ViewRay Inc. has a 12-month low of $2.69 and a 12-month high of $8.00. The firm’s 50-day moving average price is $3.45 and its 200-day moving average price is $4.19.

ViewRay (NASDAQ:VRAY) last released its earnings results on Monday, August 15th. The company reported ($0.32) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.29) by $0.03. On average, analysts forecast that ViewRay Inc. will post ($1.20) EPS for the current fiscal year.

Separately, BTIG Research began coverage on ViewRay in a report on Wednesday, September 14th. They set a “buy” rating and a $6.00 target price for the company.

ViewRay Company Profile

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

5 Day Chart for NASDAQ:VRAY

Receive News & Ratings for ViewRay Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ViewRay Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.